Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
| ▸ | ALK | Q9UM73 | 4/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | SLC12A2 | P55011 | 1/20 | 0.37 |
| ▸ | SLC12A5 | Q9H2X9 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1075687 | 0.92 | ALK (0.52) | MAPTALKJAK2 | |
| Trifluoroacetic Acid SCHEMBL4365061 | 0.88 | ALK (0.48) | MAPTALKJAK2SLC12A2SLC12A5 | |
| SCHEMBL13633131 | 0.87 | ALK (0.43) | ALKJAK2 | |
| SCHEMBL13633235 | 0.86 | ALK (0.44) | MAPTALKJAK2ALDH1A1TP53 | |
| SCHEMBL13633236 | 0.86 | ALK (0.42) | ALKJAK2NTRK1 | |
| SCHEMBL13633080 | 0.86 | ALK (0.42) | ALKJAK2NTRK1 | |
| SCHEMBL13633078 | 0.85 | ALK (0.40) | MAPTALKJAK2TP53SMN1; SMN2 | |
| SCHEMBL13633079 | 0.85 | ALK (0.44) | ALKJAK2 | |
| SCHEMBL13633061 | 0.83 | ALK (0.42) | ALKJAK2 | |
| SCHEMBL13634016 | 0.83 | JAK2 (0.43) | MAPTALKJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | JAK2, JAK1, ALK | MAPT 3239/4885ALK 3/4885JAK2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.